Biomolecules

New RNA-Based Treatments Using Antisense and Gene Editing to Target Skeletal Muscle

Updated

Abstract

Four antisense oligonucleotides have received FDA approval for treating Duchenne muscular dystrophy (DMD).

  • RNA-based therapeutics can modify RNA processing or correct disease-causing genes in skeletal muscle disorders.
  • Antisense oligonucleotides induce exon skipping to restore the reading frame for dystrophin production.
  • Current treatments face challenges such as inefficient delivery to skeletal and cardiac muscle and the need for repeat administration.
  • Next-generation approaches aim to improve cellular uptake and stability through conjugation with peptides or antibodies.
  • CRISPR-based strategies, including base and prime editing, could offer one-time corrections but raise questions about safety and delivery.

Simplified

Funding

Competing interests

T.Y. is a cofounder and shareholder of OligomicsTx Inc., which aims to commercialize antisense technology. T.K. declares no commercial or financial relationships that could be construed as a potential conflict of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • ✅direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free